

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

GENEREX BIOTECHNOLOGY CORP  
Form 8-K  
April 27, 2001

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 23, 2001  
-----

Generex Biotechnology Corporation

-----  
(Exact name of registrant as specified in its charter)

Delaware

000-25169

82-049021

-----  
(State or other jurisdiction  
of Incorporation)

-----  
(Commission  
File Number)

-----  
(IRS Employer  
Identification No.)

33 Harbor Square, Suite 202, Toronto, Ontario Canada

M5J 2G2

-----  
(Address of principal executive offices)

-----  
(Zip Code)

Registrant's telephone number, including area code

416/364-2551  
-----

-----  
(Former name or former address, if changed since last report)

Item 4. Changes in Registrant's Certifying Accountant.

On April 23, 2001, the stockholders of Generex Biotechnology Corporation ratified the selection and engagement of Deloitte & Touche L.L.P. ("Deloitte Touche") to serve as the independent public accountants to audit the financial statements of Generex and its subsidiaries for the fiscal year ending July 31, 2001. WithumSmith+Brown has been employed to perform this function for Generex since September 1998.

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

The appointment of Deloitte Touche as independent public accountants replacing WithumSmith+Brown was recommended by the Board of Directors of Generex. WithumSmith+Brown did not decline to stand for re-election and WithumSmith+Brown's reports on financial statements for the last two fiscal years did not contain an adverse opinion, disclaimer of opinion or qualification as to uncertainty, audit scope or accounting principles. There have been no disagreements with WithumSmith+Brown in the last two fiscal years on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure.

Item 7. Financial Statements and Exhibits

16. Letter from WithumSmith+Brown regarding the appointment of Deloitte Touche as independent public accountants for Generex for the fiscal year ending July 31, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEREX BIOTECHNOLOGY CORPORATION

Dated: April 27, 2001  
-----

By: /s/ E. Mark Perri  
-----

E. Mark Perri, Chairman and CFO